iRhythm(IRTC) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - iRhythm reported Q4 2025 revenue of $208.9 million, representing a 27.1% year-over-year growth, and full year 2025 revenue of $747.1 million, reflecting a 26.2% growth compared to 2024 [19][20] - The company achieved its first positive net income in Q4 2025, amounting to $5.6 million, or $0.17 per diluted share, while the full year net loss was $44.6 million, or a loss of $1.39 per diluted share [22] - Adjusted EBITDA for Q4 was $34.3 million, or 16.4% of revenue, marking a 470 basis point improvement year-over-year, and full year adjusted EBITDA was $68.9 million, or 9.2% of revenue, an improvement of over 1,000 basis points compared to 2024 [23] Business Line Data and Key Metrics Changes - The growth in Q4 was primarily driven by sustained volume demand across customer bases, with new store growth accounting for approximately 68% of year-over-year volume growth [20][21] - The Zio AT offering performed exceptionally well, with unit growth running more than twice the company average for the year [12][13] - The company holds approximately 15% market share in the MCT market, compared to 72% in long-term cardiac monitoring [14] Market Data and Key Metrics Changes - iRhythm serves approximately 40,000 primary care physicians, with more than one-third of volume originating from primary care settings [9] - The company is now commercial in the U.K., select E.U. markets, and Japan, where it holds less than 1% market share, indicating significant growth potential [14][15] - The U.K. market saw the largest quarter of volume ever for iRhythm, and the company is participating in NHS pilots [14] Company Strategy and Development Direction - iRhythm aims to shift from episodic detection to proactive, integrated, and predictive care, addressing the need for long-term continuous monitoring [8] - The company plans to focus on durable, volume-led growth across cardiology, primary care, and innovative channels, while expanding margins through operational efficiencies [16] - The strategic direction includes advancing platform innovation, scaling international markets, and maintaining operational excellence [16] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to deliver durable growth while expanding profitability, emphasizing the importance of addressing rising clinical needs and constrained access in healthcare [28][29] - The company anticipates revenue for 2026 to be in the range of $870 million-$880 million, representing 16%-18% year-over-year growth [24] - Management highlighted the importance of integrating EHR systems and predictive AI capabilities to enhance patient care and operational efficiency [10][11] Other Important Information - 2025 marked the first year of positive adjusted EBITDA and free cash flow in the company's history, demonstrating profitable growth [23][24] - The company is actively working on a next-generation MCT device, expected to be released in the first half of 2027, which will feature a 21-day wear time and enhanced algorithms [13][56] - iRhythm is positioned at the intersection of several trends, including an aging population and increasing demand for proactive health management [15] Q&A Session Summary Question: Concerns about the elimination of chart-derived diagnosis from CMS - Management addressed concerns by stating that Zio provides confirmatory diagnoses, which is crucial for integration into patient records and audit processes [32][33] Question: Guidance on gross and operating margins for 2026 - Management provided guidance for adjusted EBITDA margin of 11.5%-12.5% for 2026 and expected gross margin improvement of 80-100 basis points relative to 2025 [37] Question: Potential tailwind from CMS proposals regarding chart scraping - Management indicated that the confirmatory diagnosis provided by Zio could serve as a tailwind, as partners are focused on improving documentation and reducing costs [40][41] Question: International growth assumptions for 2026 - Management expects international growth to slightly exceed overall company growth, with significant potential in newly opened markets [43] Question: AI concerns and billing implications - Management expressed confidence in their closed platform and the quality of data, emphasizing that AI capabilities must fit within existing workflows [48][49] Question: Updates on the MCT product timeline and enhancements - Management confirmed that the MCT product is on track for a first half 2027 release, with significant enhancements including a mobile gateway and improved algorithms [55][56]